Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease
Who is this study for? Patients with Ocular Surface Disease
What treatments are being studied? Autologous Platelet Rich Plasma Eye Drops
Status: Unknown
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to evaluate prospectively the efficacy of topical administration of autologous platelet rich plasma as monotherapy for the treatment of symptoms and clinical signs in cases affected by moderate to severe forms of ocular surface disease
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• \-
Locations
Other Locations
Canada
Toronto Western Hospital
Toronto
Time Frame
Start Date: 2021-01
Completion Date: 2023-01
Participants
Target number of participants: 100
Treatments
Experimental: Treatment group
Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto